What ScinoPharm Taiwan does

ScinoPharm Taiwan is a publicly traded Taiwanese pharmaceutical company (TWSE:1789) headquartered in Tainan and founded in 1997, operating with a workforce in the 501–1,000 range. The company specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and complex generic drugs, with a particular focus on Non-Biological Complex Drugs (NBCDs). In January 2026 it became the first pharmaceutical company in Taiwan to secure U.S. FDA approval for Glatiramer Acetate Injection — a generic version of Teva's Copaxone used to treat relapsing multiple sclerosis — whose complex molecular structure containing millions of polypeptide chains required validation through more than 40 advanced analytical techniques.

Its core technology platform centers on NBCD manufacturing and characterization, combining proprietary analytical methodologies with regulatory-grade process validation. The company is pursuing parallel regulatory submissions in Europe, Asia, and emerging markets, while building strategic distribution partnerships with regional channel partners and resellers to commercialize its approved generic portfolio internationally. Business model revenue comes from selling FDA-approved generic pharmaceutical products (one-time license economics) and from licensing/royalty arrangements tied to those products, distributed through enterprise field sales and channel partner channels serving pharmaceutical distributors and healthcare providers in a B2B model.

The company's go-to-market relies on a hybrid of enterprise sales and channel/reseller partnerships, with marketing concentrated in regulatory milestone press coverage and industry conference engagement rather than consumer-facing promotion. Leadership is anchored by Li-An Lu (CEO), Tsung-Ming Su (President and CEO), Chih-Hsien Lo (Chairman and General Chief Strategy Officer), and Gloria Chang (Chief Scientific Officer). Financial details in the input appear malformed (revenue figures reported in trillions across 2021–2025 are implausible) and are not relied upon for analytical conclusions.

Name

ScinoPharm Taiwan

Legal name

ScinoPharm Taiwan

Website

https://scinopharm.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

ScinoPharm Taiwan is a public Taiwanese pharmaceutical manufacturer (TWSE:1789) specializing in APIs and complex generic drugs, and the first Taiwanese firm to secure FDA approval for Glatiramer Acetate Injection to treat multiple sclerosis.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Active pharmaceutical ingredients
• Generic drug manufacturing
• Contract development manufacturing
• Non-biological complex drugs
• Pharmaceutical API production

Headquarters

HQ city

Tainan

HQ country

Taiwan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

1. Generic Pharmaceutical Products: Revenue generated from manufacturing and selling FDA-approved generic pharmaceutical products. The company specializes in complex generic drugs that face significant manufacturing challenges due to non-biological complex structures.
2. Generic Drug Product Market Expansion: Revenue from regulatory submissions and partnerships across Europe, Asia, and emerging markets for generic drug products, expanding global market presence.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

ScinoPharm Taiwan is a pharmaceutical contract manufacturer that produces active pharmaceutical ingredients (APIs) and complex generic drug products. Its flagship commercial product is Glatiramer Acetate Injection, which received U.S. FDA approval as the first complex generic drug approved in Taiwan. The company applies specialized non-biological complex drug (NBCD) manufacturing technology and more than 40 analytical techniques for complex polypeptide validation.

Product overview

ScinoPharm Taiwan operates as a pharmaceutical contract manufacturing company specializing in active pharmaceutical ingredients (APIs) and complex generic drugs. The company's primary product is Glatiramer Acetate Injection, a Non-Biological Complex Drug approved by the FDA for treating multiple sclerosis. The company is pursuing regulatory submissions in Europe, Asia, and emerging markets to expand its global presence in the generic drug product market. The global market for Glatiramer Acetate was valued at USD 1.5 billion in 2024 and is projected to reach USD 2.8 billion by 2033, with the U.S. market estimated at approximately USD 700 million.

Differentiator

Problem solved

Functional benefit

Products and services

• Glatiramer Acetate Injection FDA-approved complex generic injectable drug product based on a non-biological complex drug (NBCD) polypeptide, supplied to pharmaceutical distributors and healthcare providers for commercial distribution.
• Active Pharmaceutical Ingredients (APIs) Contract-manufactured active pharmaceutical ingredients supplied to pharmaceutical companies for use in finished drug formulations.

Quantifiable outcome

• Global Glatiramer Acetate market valued at USD 1.5 billion in 2024, projected to reach USD 2.8 billion by 2033

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Strategic Partners (Europe, Asia, Emerging Markets)coreChannel Partner/ Reseller/ DistributorScinoPharm is pursuing regulatory submissions and forging strategic partnerships across Europe, Asia, and emerging markets to expand global presence in the generic drug product market. These partnerships enable distribution and commercialization of FDA-approved generic pharmaceutical products.

Scale indicators5 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Teva Pharmaceutical Industries: Originator of Copaxone (Glatiramer Acetate brand), the product ScinoPharm is now generic-manufacturing. Most directly comparable competitor and reference point for the underlying market dynamics ScinoPharm is targeting.
• Dr. Reddy's Laboratories: Indian-headquartered global generics and API manufacturer with a complex generics portfolio across CNS and other therapeutic areas. Closely comparable in dual API-plus-generic-finished-dose business model targeting regulated markets.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with a broad complex-generics portfolio. Comparable in targeting the U.S. and other regulated markets with FDA-approved generic products.
• Viatris (formerly Mylan): Large global generic pharmaceutical company with extensive complex generic and biosimilar portfolio. Directly comparable in business model, target customers (distributors/healthcare providers), and API-to-finished-dose capabilities.
• Aurobindo Pharma: Vertically integrated API and generic finished-dose manufacturer with strong U.S. and emerging-market presence. Highly comparable in manufacturing complexity, regulatory filings, and channel-partner distribution model.
• Cipla: Indian-headquartered global pharmaceutical manufacturer with strong API and complex generics presence across respiratory, CNS, and other therapeutic categories. Comparable in API-plus-finished-dose model and emerging-market expansion strategy.
• Bora Pharmaceuticals: Taiwan-based CDMO and specialty generics company with FDA-inspected facilities. Most regionally comparable peer given shared Taiwan domicile, similar CDMO/generics business model, and parallel FDA approval track record.
• Hikma Pharmaceuticals: Specialty generic pharmaceutical company with strong injectables and complex generics portfolio. Highly comparable in targeting U.S. and European markets with complex injectable products via strategic distribution partnerships.
• Sun Pharmaceutical Industries: India's largest specialty generic pharmaceutical company with significant complex generics and injectables portfolio. Comparable in pursuing FDA approvals and international distribution partnerships across multiple regions.

Broad incumbents

• Sandoz (Novartis): Global leader in generics and biosimilars with broad portfolio. Overlaps significantly with ScinoPharm in complex generics but operates at much greater scale and across many more therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScinoPharm Taiwan